PRO-240
Phase 1Small molecule
PRO-240 is one of 31 small molecule programs targeting MPA. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
48 competitors in MPA
#DrugCompanyPhaseTrials
1Repatha
AmgenApproved
Activella
Eli LillyApproved
Tremfya
Johnson & JohnsonApproved
Jardiance
Boehringer IngelheimApproved
Rituxan
RochePhase 3
Nitrostat
VViatris Specialty LLC
Phase 2
Obicetrapib
NNewAmsterdam Pharma
Phase 2
Heparin Sodium
BBaxter Healthcare Corporation
Phase 1
XTR004
SSinotau Pharmaceutical Group
Phase 3
Uloric
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRO-240. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- LLaboratorios Sophia S.A de C.V.